PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer
Top Cited Papers
Open Access
- 6 June 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 113 (12), 1733-1743
- https://doi.org/10.1093/jnci/djab108
Abstract
Background: In the phase III IMpassion130 study, atezolizumab plus nab-paclitaxel (A+nP) showed clinical benefit in advanced or metastatic triple-negative breast cancer patients who were programmed death-ligand 1 (PD-L1) + (tumor-infiltrating immune cells [IC] >= 1%) using the SP142 immunohistochemistry assay. Here we evaluate 2 other PD-L1 assays for analytical concordance with SP142 and patient-associated clinical outcomes. Methods: Samples from 614 patients (68.1% of intention-to-treat population) were centrally evaluated by immunohistochemistry for PD-L1 status on IC (VENTANA SP142, SP263, Dako 22C3) or as a combined positive score (CPS; 22C3). Results: Using SP142, SP263, and 22C3 assays, PD-L1 IC >= 1% prevalence was 46.4% (95% confidence interval [CI] = 42.5% to 50.4%), 74.9% (95% CI = 71.5% to 78.3%), and 73.1% (95% CI = 69.6% to 76.6%), respectively; 80.9% were 22C3 CPS >= 1. At IC >= 1% (+), the analytical concordance between SP142 and SP263 and 22C3 was 69.2% and 68.7%, respectively. Almost all SP142+ cases were captured by other assays (double positive), but several SP263+ (29.6%) or 22C3+ (29.0%) cases were SP142- (single positive). A+nP clinical activity vs placebo+nP in SP263+ and 22C3+ patients (progression-free survival [PFS] hazard ratios [HRs] = 0.64 to 0.68; overall survival [OS] HRs = 0.75 to 0.79) was driven by double-positive cases (PFS HRs = 0.60 to 0.61; OS HRs = 0.71 to 0.75) rather than single-positive cases (PFS HRs = 0.68 to 0.81; OS HRs = 0.87 to 0.95). Concordance for harmonized cutoffs for SP263 (IC >= 4%) and 22C3 (CPS >= 10) to SP142 (IC >= 1%) was subpar (approximately 75%). Conclusions: 22C3 and SP263 assays identified more patients as PD-L1+ (IC >= 1%) than SP142. No inter-assay analytical equivalency was observed. Consistent improved A+nP efficacy was captured by the SP142 PD-L1 IC similar to 1% subgroup nested within 22C3 and SP263 PD-L1+ (IC >= 1%) populations.Funding Information
- F. Hoffmann-La Roche, Ltd/Genentech, Inc
- Roche Group
This publication has 29 references indexed in Scilit:
- Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for AtezolizumabApplied Immunohistochemistry & Molecular Morphology, 2019
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast CancerJAMA Oncology, 2019
- Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosisNature Medicine, 2018
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 ProjectJournal of Thoracic Oncology, 2018
- PD-L1 in breast cancer: comparative analysis of 3 different antibodiesHuman Pathology, 2018
- Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung CancerScientific Reports, 2017
- Comparison of Four PD-L1 Immunohistochemical Assays in Lung CancerJournal of Thoracic Oncology, 2017
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison ProjectJournal of Thoracic Oncology, 2017
- A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1JAMA Oncology, 2017
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Annals of Oncology, 2014